Medica Corp
MA - Bedford
Diagnostics3 H-1B visas (FY2023)Focus: In-vitro diagnostic analyzers
Medica Corp is a life sciences company focused on In-vitro diagnostic analyzers.
OncologyCardiovascularNeurologyImmunologyHematology
Open Jobs
0
Products & Portfolio (31)
19 discontinued products not shown
AMMONIA N 13
nh3n13
LOE Approaching
INTRAVENOUS · INJECTABLE
Radiopharmaceutical Activity
2007
30
AMMONIA N 13
ammonia n-13
Post-LOE
INTRAVENOUS · INJECTABLE
2013
30
AMMONIA N 13
ammonia n-13
Post-LOE
INTRAVENOUS · INJECTABLE
2015
30
APREMILAST
apremilast
Post-LOE
ORAL · TABLET
4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP levels. The specific mechanism(s) by which apremilast exerts its therapeutic action is not well defined.
olderweighing at least 20 kg with active psoriatic arthritisweighing at least 50 kg with active psoriatic arthritis+4 more
2023
30
ATORVASTATIN CALCIUM
atorvastatin calcium
Post-LOE
ORAL · TABLET
Hydroxymethylglutaryl-CoA Reductase Inhibitors
type 2 diabetes mellitusheart failure
2020
30
ATROPINE SULFATE
atropine sulfate
Post-LOE
INTRAVENOUS · SOLUTION
muscarine-like actions of acetylcholine and other choline esters. Atropine inhibits the muscarinic actions of acetylcholine on structures innervated by postganglionic cholinergic nerves, and on smooth muscles which respond to endogenous acetylcholine but are not so innervated. As with other antimuscarinic agents, the major action of atropine is a competitive or surmountable antagonism which can be overcome by increasing the concentration of acetylcholine at receptor sites of the effector organ (e.g., by using anticholinesterase agents which inhibit the enzymatic destruction of acetylcholine). The receptors antagonized by atropine are the peripheral structures that are stimulated or inhibited by muscarine (i.e., exocrine glands and smooth and cardiac muscle). Responses to postganglionic cholinergic nerve stimulation also may be inhibited by atropine but this occurs less readily than with responses to injected (exogenous) choline esters.
2020
30
AZACITIDINE
azacitidine
Post-LOE
INTRAVENOUS, SUBCUTANEOUS · POWDER
Nucleic Acid Synthesis Inhibitors
refractory anemia with ringed sideroblasts (if accompanied by neutropeniathrombocytopeniarequiring transfusions)+5 more
2016
30
BORTEZOMIB
bortezomib
Growth
INTRAVENOUS, SUBCUTANEOUS · SOLUTION
Proteasome Inhibitors
myelomalymphoma
2024
30
BUSULFAN
busulfan
Post-LOE
INJECTION · INJECTABLE
Alkylating Activity
leukemia
2019
30
CALCIUM CHLORIDE 10%
calcium chloride
Post-LOE
INJECTION · INJECTABLE
12.1 Mechanism of Action Intravenous administration of calcium chloride increases serum ionized calcium concentration. Calcium chloride dissociates into ionized calcium in plasma. 12.2 Pharmacodynamics The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of Calcium Chloride Injection have not been fully characterized. 12.3 Pharmacokinetics Absorption Calcium Chloride Injection is 100% bioavailable following intravenous injection. Distribution Calcium in the body is distributed mainly in skeleton (99%) and 1% is distributed within the extracellular fluids and soft tissues. About 50% of total serum calcium is in the ionized form and represents the biologically active part; 8% to 10% serum calcium is bound to organic and inorganic acid, respectively; and approximately 40% is protein-bound (primarily to albumin). Elimination Metabolism Calcium itself does not undergo direct metabolism. Excretion Calcium is excreted by the kidney through a combination of glomerular filtration and tubular reabsorption. A significant increase in urinary excretion of calcium was observed during and after intravenous infusion of calcium chloride. Specific Populations The effect of age, sex, race, ethnicity, renal or hepatic impairment on the pharmacokinetics of calcium have not been evaluated in clinical studies.
2018
30
CAPECITABINE
capecitabine
Post-LOE
ORAL · TABLET
Nucleic Acid Synthesis Inhibitors
an anthracycline-containing chemotherapy regimenresistant to paclitaxelfor whom further anthracycline therapy is not indicated (e+2 more
2016
30
CARBAMAZEPINE
carbamazepine
Post-LOE
ORAL · TABLET
Cytochrome P450 3A4 Inducers
the treatment of the pain associated with true trigeminal neuralgiaEpilepsy
2020
30
Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Founded: 1983
Portfolio: 128 approved products, 11 clinical trials
Top TAs: Oncology, Cardiovascular, Neurology
H-1B (2023): 3 approvals
Portfolio Health
Pre-Launch23 (18%)
Launch1 (1%)
Growth2 (2%)
Peak4 (3%)
LOE Approaching19 (15%)
Post-LOE79 (62%)
128 total products
Therapeutic Area Focus
Oncology
9 marketed
Cardiovascular
8 marketed
Neurology
6 marketed2 pipeline
Immunology
5 marketed
Psychiatry
4 marketed
Respiratory
4 marketed
Hematology
3 marketed
Metabolic Diseases
2 marketed
Marketed
Pipeline
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
3
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub